Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev
Trending
Indices
US
Crypto
Forex
Commodities
Futures
SYMBOL
LAST
NET CHG.
%CHG.
HIGH
LOW
- All
- Chatrooms
- Groups
- Friends
Connecting
.
.
.
US
VN
TW
- All
- US Election
- Israel-Palestine Conflict
- Russia-Ukraine Conflict
Search
News
Trending Topics
Daily News
To quickly learn market dynamics and follow market focuses in 15 min.
Remarks of Officials
In the world of mankind, there will not be a statement without any position, nor a remark without any purpose.
Central Bank
Inflation, exchange rates, and the economy shape the policy decisions of central banks; the attitudes and words of central bank officials also influence the actions of market traders.
Forex
Money makes the world go round and currency is a permanent commodity. The forex market is full of surprises and expectations.
Latest Update
Risk Warning on Trading HK Stocks
Despite Hong Kong's robust legal and regulatory framework, its stock market still faces unique risks and challenges, such as currency fluctuations due to the Hong Kong dollar's peg to the US dollar and the impact of mainland China's policy changes and economic conditions on Hong Kong stocks.
HK Stock Trading Fees and Taxation
Trading costs in the Hong Kong stock market include transaction fees, stamp duty, settlement charges, and currency conversion fees for foreign investors. Additionally, taxes may apply based on local regulations.
HK Non-Essential Consumer Goods Industry
The Hong Kong stock market encompasses non-essential consumption sectors like automotive, education, tourism, catering, and apparel. Of the 643 listed companies, 35% are mainland Chinese, making up 65% of the total market capitalization. Thus, it's heavily influenced by the Chinese economy.
HK Real Estate Industry
In recent years, the real estate and construction sector's share in the Hong Kong stock index has notably decreased. Nevertheless, as of 2022, it retains around 10% market share, covering real estate development, construction engineering, investment, and property management.
Recent Searches
Top Searches
View All
No data
Search
Zentalis Stock Up as FDA Lifts Partial Hold on Cancer Drug Studies
Zacks
Shares of Zentalis Pharmaceuticals ZNTL gained 13.6% on Monday after it announced that the FDA has lifted the partial clinical hold previously imposed on three studies of the company’s lead product candidate, azenosertib, for three different cancer indications. The decision was based on the regulatory body’s review of Zentalis’ complete response package, which included a comprehensive safety assessment of the azenosertib program.
Zentalis’ azenosertib, a potentially first-in-class oral WEE1 inhibitor, is currently being studied as a monotherapy and in combination with other therapies for treating different types of cancer indications, including solid tumors and ovarian cancer.
Per Zentalis, the FDA has given the green light to resume enrollment in all ongoing azenosertib clinical studies with no changes in the clinical development plan. The company is gearing up to resume study activities across the azenosertib development program at the earliest.
Year to date, shares of Zentalis have plunged 75.7% against the industry’s 0.5% growth.
Developmental Setbacks Faced by ZNTL for Azenosertib
In June 2024, the FDA placed a partial clinical hold on the following azenosertib studies — the phase I ZN-c3-001 dose-escalation for solid tumors, the phase II ZN-c3-005 DENALI study for platinum-resistant ovarian cancer (PROC) and the phase II ZN-c3-004 TETON study for uterine serous carcinoma.
This action was taken by the regulatory body after two patients in the DENALI study died due to presumed sepsis. This resulted in a huge dip in Zentalis’ share price back then.
In its second-quarter earnings release, Zentalis announced that it has discontinued the development of the combination of its BCL-2 inhibitor, ZN-d5, with azenosertib due to unsatisfactory efficacy data. The combo therapy was evaluated in a phase I study for the treatment of relapsed or refractory acute myeloid leukemia.
ZNTL’s Future Clinical Development Plan for Azenosertib
ZNTL has already completed enrollment in cohort 1b of the DENALI study. Overall efficacy and safety data from the same is expected to be announced later in 2024. Zentalis also plans to present data from the ZN-c3-001 and the MAMMOTH studies later in the ongoing year.
The phase I/II MAMMOTH (ZN-c3-006) study is evaluating azenosertib in combination with GSK’s GSK PARP inhibitor Zejula (niraparib) and azenosertib as monotherapy for treating PROC.
The study is being conducted in partnership with GSK.
GSK’s Zejula is already approved for ovarian cancer and is currently being studied for additional ovarian cancer stages as well as non-small cell lung cancer and endometrial cancer.
Per the latest press release, Zentalis is scheduled to present azenosertib monotherapy data and provide additional updates on the azenosertib clinical development program and other data presentation timelines at an upcoming medical conference.
Zentalis Pharmaceuticals, Inc. Price and Consensus
Zentalis Pharmaceuticals, Inc. price-consensus-chart | Zentalis Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Zentalis currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Illumina, Inc. ILMN and Fulcrum Therapeutics, Inc. FULC, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Illumina’s 2024 earnings per share have moved up from $1.84 to $3.62. The consensus estimate for 2025 earnings has improved from $3.22 to $4.43. Year to date, shares of ILMN have lost 7%.
ILMN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 463.46%.
In the past 60 days, estimates for Fulcrum Therapeutics’ 2024 loss per share have narrowed from $1.24 to 33 cents. The consensus estimate for 2025 loss per share has narrowed from $1.71 to $1.14. Year to date, shares of FULC have plunged 52.9%.
FULC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 393.18%.
Zacks Investment Research
Risk Warnings and Disclaimers
You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
Copyright © 2024 FastBull Ltd
728 RM B 7/F GEE LOK IND BLDG NO 34 HUNG TO RD KWUN TONG KLN HONG KONG
Risk Disclosure
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.